Europe — EMA
Mivacurium Kalceks
GNH USA supplies Mivacurium Kalceks (Mivacurium), a neuromuscular blocking agent for facilitation of endotracheal intubation and muscle relaxation during
Request sourcing
What is Mivacurium?
Mivacurium, the active ingredient in Mivacurium Kalceks, is a neuromuscular blocking agent presented as an injectable solution for intravenous use. It provides short‑acting skeletal muscle relaxation to facilitate endotracheal intubation and to support muscle relaxation during surgical procedures in adult patients under anesthesia.
GNH USA supplies Mivacurium Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company follows stringent quality standards and offers reliable global logistics to ensure timely delivery for clinical and surgical use. GNH USA’s dedicated regulatory team assists with import documentation and compliance across regions.
What is Mivacurium used for?
Mivacurium is a short‑acting neuromuscular blocking agent used in anesthesia to produce rapid skeletal muscle relaxation.
- Facilitation of endotracheal intubation: provides rapid, short‑duration muscle relaxation to allow safe airway placement. - Muscle relaxation during surgery: enables controlled relaxation of skeletal muscles throughout operative procedures. - Diagnostic procedures requiring brief neuromuscular blockade: allows temporary paralysis for specific investigations such as bronchoscopy.
What are the side effects of Mivacurium?
Mivacurium may be associated with a range of adverse reactions, varying from mild to severe.
Common Side Effects: - Transient flushing or erythema - Mild hypotension - Tachycardia - Bronchospasm - Nausea or vomiting - Headache
Serious or Rare Side Effects: - Anaphylactic reaction - Prolonged apnea or respiratory depression - Malignant hyperthermia - Severe hypotension or cardiovascular collapse - Cardiac arrest
What precautions apply to Mivacurium?
When using Mivacurium, clinicians should observe several precautionary measures to ensure patient safety.
- Assess neuromuscular function: perform baseline monitoring before administration. - Monitor respiratory status: observe for apnea and ensure ventilatory support is available. - Avoid in patients with known hypersensitivity: discontinue immediately if allergic reaction occurs. - Use with caution in hepatic or renal impairment: altered metabolism may prolong effects. - Adjust dosing in the elderly or frail patients: consider reduced dose to prevent prolonged blockade. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Mivacurium interact with?
Mivacurium can interact with other agents that influence neuromuscular transmission or cardiovascular stability.
Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): potentiate neuromuscular blockade. - Magnesium sulfate: enhances block and may cause prolonged paralysis. - Other neuromuscular blocking agents: additive effects increase risk of respiratory failure. - Lithium therapy: may increase sensitivity to blockade.
Moderate Interactions (Monitor Closely): - Volatile anesthetic gases (e.g., sevoflurane): can augment the depth of block. - Calcium channel blockers (e.g., verapamil): may slightly increase blockade duration. - Beta‑adrenergic blockers (e.g., propranolol): may affect cardiovascular response during administration.
